文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

瑞士HIV队列研究:强效抗逆转录病毒治疗下获得性耐药在社会弱势患者中出现

Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该病例对照研究纳入瑞士HIV队列研究中1996年后启动首次cART的115例获得性耐药病例和115例匹配对照,通过系统病历回顾分析危险因素。多变量模型显示失业、非洲来源、合并抗感染药物及精神疾病症状与获得性耐药相关,提示社会弱势或心理健康问题的患者耐药风险更高。

要点

  • 失业、非洲来源、合并抗感染药物及精神疾病症状与获得性耐药独立相关。
  • 尽管cART时代获得性耐药已非常罕见,社会弱势患者仍存在耐药风险。
  • 应在获得性耐药发生前及时识别并给予充分支持,以防止治疗失败和HIV传播。

核心结论

  • 尽管强效cART使获得性耐药变得非常罕见,但处于社会困境或存在心理健康问题的患者耐药风险更高。
  • 及时识别并充分支持这些患者可预防治疗失败和HIV-1传播。

研究设计与样本

  • 病例对照研究,纳入瑞士HIV队列研究中自1996年起启动首次cART的全部患者。
  • 瑞士HIV队列研究具有高度代表性,覆盖瑞士接受抗逆转录病毒治疗超过75%的患者。
  • 通过系统病历回顾获取队列常规未收集的详细参数,采用单变量和多变量条件logistic回归分析。
  • 共纳入115例病例和115例匹配对照。

临床怎么用

  • 对启动cART的患者应评估失业、移民来源、合并抗感染用药及精神疾病症状等社会心理因素。
  • 对存在社会困境或心理健康问题的患者应在获得性耐药发生前及时识别并提供充分支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The rate of acquired human immunodeficiency virus type 1 (HIV-1) drug resistance (ADR) has fallen dramatically since introduction of combined antiretroviral therapy (cART) in Switzerland. However, clinical experience indicates that there are still patients at risk of newly acquiring drug resistance despite having access to cART. Here, we characterized risk factors for ADR, to improve patient care and prevent emergence of drug resistance and treatment failure. METHODS: We performed a case-control study to identify risk factors for ADR in all patients starting their first cART in the Swiss HIV Cohort Study (SHCS) since 1996. The SHCS is highly representative and includes >75% of patients receiving ART in Switzerland. To this end, we implemented a systematic medical chart review to obtain more detailed information on additional parameters, which are not routinely collected in the SHCS. The collected data were analyzed using univariable and multivariable conditional logistic regression. RESULTS: We included in our study 115 cases and 115 matched controls. Unemployment (multivariable odds ratio [mOR], 2.9 [95% confidence interval {CI}, 1.3-6.4]; P = .008), African origin (mOR, 3.0 [95% CI, 1.0-9.2]; P = .047), comedication with anti-infectives (mOR, 3.7 [95% CI, 1.0-12.6]; P = .045), and symptoms of mental illness (mOR, 2.6 [95% CI, 1.2-5.5]; P = .012) were associated with ADR in the multivariable model. CONCLUSIONS: Although ADR has become very rare with cART due to new potent therapies, patients in socially challenging life situations or presenting with mental health issues are at higher risk for drug resistance. Prompt identification and adequate support of these patients before ADR will prevent treatment failure and HIV-1 transmission.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Abela IA, Scherrer AU, Böni J, et al. Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. Clin Infect Dis. 2020. PMID: 30843028. doi:10.1093/cid/ciz178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。